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Abstract: There is an urgent need for novel and improved drugs against several tropical 
diseases caused by protozoa. The marine sponge (Agelas sp.) metabolite agelasine D, as 
well as other agelasine analogs and related structures were screened for inhibitory activity 
against Plasmodium falciparum, Leishmania infantum, Trypanosoma brucei and T. cruzi, 
as well as for toxicity against MRC-5 fibroblast cells. Many compounds displayed high 
general toxicity towards both the protozoa and MRC-5 cells. However, two compounds 
exhibited more selective inhibitory activity against L. infantum (IC50 <0.5 μg/mL) while 
two others displayed IC50 <1 μg/mL against T. cruzi in combination with relatively low 
toxicity against MRC-5 cells. According to criteria set up by the WHO Special Programme 
for Research & Training in Tropical Diseases (TDR), these compounds could be classified 
as hits for leishmaniasis and for Chagas disease, respectively. Identification of the hits as 
well as other SAR data from this initial screening will be valuable for design of more 
potent and selective potential drugs against these neglected tropical diseases. 
Keywords: Agelasine; Antiprotozoal; Chagas disease; Visceral leishmaniasis. 
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Introduction  
Several so-called neglected diseases, e.g. illnesses that disproportionally affect poor and 
marginalized populations and for which satisfactory treatment is not available, partly due to lack of 
interest in drug development, are due to protozoal infections. Major killers in developing countries 
include malaria [1-2], visceral leishmaniasis or kala-azar [3-4], African sleeping sickness [4-5] and 
American sleeping sickness or Chagas disease [6]. Several factors limit the utility of existing drugs in 
areas were they are really needed, for instance high cost, poor compliance, drug resistance, low 
efficacy and toxicity [7]. Current drugs used to treat Trypanosoma infections are unsatisfactory with 
respect to safety [6] and an increasing number of malaria cases are caused by Plasmodium falciparum 
resistant to first-line drugs [1-2]. Hence, there is a constant need for development of novel 
antiprotozoal drugs, and one strategy in search for new hits and leads is screening of natural products, 
including those found in marine organisms [8]. 
Agelasines are isolated from marine sponges (Agelas sp) [9-17]. We have completed the first 
syntheses of agelasine D [18-19], agelasine E [20] and ent-agelasine F [21] as well as several synthetic 
analogs [18-20, 22-24]. It has been shown that many of these compounds possess a broad spectrum of 
biological activities; including cytotoxicity towards cancer cell lines [19, 22-23], antibacterial- [19-
23], antifungal [23] and antifouling activities [25]. Recently, we also demonstrated that some agelasine 
analogs displayed antiprotozoal activity (Acanthamoeba castellanii and A. polyphaga) [22]. Hence we 
chose to screen agelasine D and some agelasine analogs and structurally related compounds for 
activity against pathogenic protozoa causing the above mentioned tropical neglected diseases. The 
structures of the compounds studied are shown in Figure 1. Compounds 8 and 9 may be regarded as 
analogs of agelasimines, another class of purine-containing natural products isolated from Agelas sp. 
[26-27].  
Results and Discussion 
Antiprotozoal activities 
The marine sponge metabolite agelasine D (2c) was screened for in vitro activity against the 
pathogenic protozoa P. falciparum, Leishmania infantum, Trypanosoma cruzi, and Trypanosoma 
brucei (Table 1). To assess selectivity of action, cytotoxicity against MRC-5 fibroblast cells was also 
evaluated. A higher activity was found for agelasine D (2c; IC50 0.29 μg/mL = 0.63 μM) against P. 
falciparum than what was recently reported for agelasines J (IC50 6.6 μM), K (IC50 8.3 μM), and L 
(IC50 18 μM) [17]. The selectivity index for antimalarial action [SI; IC50(MRC-5 fibroblast)/IC50(P. 
falciparum)] was 23, and agelasine D (2c) displayed significant inhibitory action also against the other 
parasites examined. These results encouraged us to examine the antiprotozoal activities of a number of 
agelasine analogs 1 – 9 in search for more potent and selective compounds. The results are presented 
in Table 1. Compounds with high cytotoxicity and related aspecificity across the different models were 
not titrated down to the exact IC50 as they may never become relevant hits for further follow-up. 
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Figure 1. Structures of the studied agelasine analogs 1-9. 
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For an antimalaria hit, the WHO Special Programme for Research & Training in Tropical Diseases 
(TDR) defines an activity criterion to be IC50 <0.2 μg/mL with SI >20 [28]. Only compound 1d, with 
IC50 = 0.10 μg/mL and SI = 20, met this requirement. However, this compound also showed 
comparable levels of activity against the other parasite species, suggesting aspecific action. A few 
other analogues [1a – 1c, 1f, 1j, 1m – 1o, in addition to 2c (agelasine D)] displayed IC50 values against 
P. falciparum in the range 0.2 – 1.0 μg/mL, while compounds 3 – 9 were in general only marginally 
active.  
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Compound 1d was found to be a potent in vitro inhibitor of L. infantum with an IC50 value of 0.093 
μg/mL and SI = 22. This compound meets the definition of a hit according to TDR (IC50 <0.5 μg/mL 
and SI >20) [28]. Compound 5 also classifies as a hit. We have previously shown that compound 1d 
displays a rather broad spectrum of antibacterial activities, incl. inhibition of Mycobacterium 
tuberculosis [19, 23], whereas the imidazole 5 were reasonably active against Staphyllococcus aureus, 
but not against Escherichia coli and M. tuberculosis [23]. Compounds 1f and 1j appeared also as 
potent inhibitors of L. infantum, but unfortunately these compounds were equally toxic to MRC-5 
cells. Compounds 3 – 4 and 6 – 9 were in general only weakly active against L. infantum. 
Quite a few of the agelasine analogs inhibited T. cruzi growth, as they displayed IC50 values <1 
μg/mL [28], but particularly compounds 1 also exhibited profound cytotoxicity towards MRC-5 cells, 
which is also the host cell in the T. cruzi model. Nevertheless, compounds 2a and 5, with SI >50, could 
be classified as hits according to the definition given above. Agelasine analog 2a is of special interest, 
since this compound, in contrast to the imidazole 5, displays low inhibitory activity against the other 
protozoa. In addition, previous studies have revealed the compound 2a is virtually inactive against 
bacteria (S. aureus, E. coli and M. tuberculosis) [23]. Moderate toxicity (SI = 10 – 30) and IC50 against 
T. cruzi <1 μg/mL were found also for compounds 1d, 3f and 9. 
None of the compounds examined qualified as a hit with respect to T. b. brucei (IC50 <0.2 μg/mL 
and SI >100) [28]. The majority of active compounds were far too toxic. The most interesting results 
were found for compound 5 with IC50 <0.11 μg/mL and SI >69. 
Structure – activity relationships 
From the results in Table 1, it can be seen that type 1 compounds (Figure 1) generally exhibit a 
broad spectrum of antiprotozoal activities, but in an aspecific manner, since many of these compounds 
are equally toxic towards MRC-5 cells. Compounds with a monoterpene- (eg. 1a), or sesquiterpene 
(1b and 1c) derived side-chain in the purine 7-position appear to be more toxic, compared to some of 
the compounds with longer side-chains. Among the diterpenoids, a phytyl substituent (1j and 1k) and 
the β-cyclocitral derived side-chain found in 1l and 1m, also results in aspecific activity. The most 
interesting compounds in this class have a geranylgeranyl side-chain or the same diterpenoid 
substituent as found in agelasine D (2c). Compounds 1d and 1n, both carrying a methoxy group at N6 
and a methyl group at N-9, were identified as antileishmanial hits. A trend seems to be that changing 
the N6 substituents from methoxy to a benzyloxy- (compounds 1c, 1e, 1h, 1k, and 1l) or tert-butoxy 
group (1f, 1m, and 1o) generally results in compounds with enhanced selectivity towards 
Trypanosoma sp., compared to the other parasites, but this modification does not result in significant 
reduction of MRC-5 cytotoxicity. Similar results were obtained when the N-9 substituent differed from 
methyl (1g – 1i). 
Agelasine D and analogs 2 have a primary amino group in the purine 6-position, instead of the 
alkoxyamino group found in compounds 1. This generally results in reduced cytotoxicity and 
improved selectivity for antiprotozoal activity. Agelasine analog 2a is a quite selective hit with respect 
to inhibition of T. cruzi. Since only three compounds of this class (2a – 2c) were included in this initial 
screening, few other conclusions regarding SAR can be drawn at this point. 
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Table 1. Activity of compounds 1 – 9 against P. falciparum, L. infantum, T. cruzi and T. b. 
brucei, as well as MRC-5 fibroblast cells. 
Compound No.a 
P. falciparum L. infantum T. cruzi T. b. brucei MRC-5 
IC50 
μg/mLb 
(<0.2 
μg/mL)c 
SId 
(>20)c 
 
IC50 
μg/mLe 
(<0.5 
μg/mL)c 
SId 
(>20)c 
IC50 
μg/mf 
(<1.0 
μg/mL)c 
SId 
(>50)c 
IC50 
μg/mLg 
(<0.2 
μg/mL)c 
SId 
(>100)c 
IC50 
μg/mL 
 
1a 0.46 1.9 7.5 <1 <0.079 >11 1.9 <1 0.86 
1b 0.63 <1 0.77 <1 <0.096 >3.6 0.20 1.8 0.35 
1c 0.74 <1 0.99 <1 <0.11 >2.8 <0.11 >2.8 0.31 
1d 0.10  20 0.093 22 0.11  18 0.23  8.7 2.0 
1e 4.2 <1 5.4 <1 1.4 2.3 0.29 11 3.2 
1f 0.26 1.0 0.27 <1 <0.12 >2.2 <0.12 >2.2 0.26 
1g 5.3 <1 12 <1 0.81 <1 1.0 <1 0.49 
1h 10 <1 18 <1 3.0 1.2 1.7 2.1 3.5 
1i 3.5 <1 1.2 <1 1.3 <1 0.29 3.2 0.92 
1j 0.30 <1 0.23 <1 <0.11 >1.9 0.11 1.9 0.21 
1k 7.3 <1 1.3 <1 <0.13 >2.2 <0.13 >2.2 0.28 
1l 1.3 <1 12 <1 0.14 3.8 <0.13 >4.1 0.53 
1m 0.69 <1 0.99 <1 <0.12 >4 <0.12 >4 0.48 
1n 0.29  16 0.63 7.1 0.49  9.2 0.30 15 4.5 
1o 0.94 <1 4.0 <1 <0.12 >3.8 <0.12 >3.8 0.45 
2a 2.9 >9.0 >26 _ 0.43 >60 13 >2 >26 
2b 0.96 <1 2.9 <1 <0.12 >6.3 0.23 3.3 0.75 
2c (Agelasine D) 0.29  23 1.5  4.5 4.5  1.5 0.90 7.4 6.7 
3a 10 1.1 >26 <1 2.5 4.4 2.3 4.8 11 
3b 3.9 3.1 >29 <1 3.6 3.3 2.6 4.6 12 
3c 1.8 <1 2.7 <1 <0.13 >2.4 <0.13 >2.4 0.31 
3d 2.3 1.1 >36 <1 2.2 1.1 1.2 2.1 2.5 
3e 3.5 6 >44 <1 4.5 3.3 1.3 12 15 
3f >29 <1 >29 <1 0.77 3.5 2.7 1.0 2.7 
3g >26 _ 9.8 >2.7 0.97 >27 2.9 >9.0 >26 
4a 9.4 <1 >26 <1 2.3 1.1 3.5 <1 2.6 
4b >28 <1 >28 <1 0.28 7.5 0.89 2.4 2.1 
4c 25 <1 >33 <1 1.5 1.0 3.8 <1 1.5 
5 0.97 7.8 <0.11 >69 <0.11 >69 <0.11 >69 7.6 
6 1.0 2.0 2.5 >69 <0.12 >17 0.19 11 2.0 
7 10 1.6 >32 >69 11 1.5 4.1 3.9 16 
8 3.37 >69 13 >69 0.19 12 0.63 3.7 2.3 
9 >28 _ >28 _ 3.2 >8.8 14 >2 >28 
(a) The structures can be found in Figure 1; (b) Chloroquine 0.04 μg/mL; (c) Activity/safety criteria for 
an antiprotozoal hit according to TDR [28]; (d) SI = IC50(fibroblast)/IC50(parasite); (e) Miltefosine 0.24 
μg/mL; (f) Benznidazole 0.25 μg/mL; (g) Melarsoprol 0.005 μg/mL. 
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Compounds 3a – 3e are neutral isomers of compounds 1. In general, they exhibit rather low 
antiprotozoal activities, with exception of compound 3c, which is a potent but non-selective inhibitor 
of Trypanosoma sp. 9-Geranylgeranyladenine 3f was a quite selective T. cruzi inhibitor with only 
moderate toxicity. 
N-9 Dealkylation of compounds 1 and 2 results in derivatives with the general structure 4. This 
modification was particularly detrimental for antiplasmodial and antileishmania activity, while 
antitrypanosomal activities were also somewhat reduced and toxicity towards MRC-5 cells was 
virtually unchanged or even increased (cf. 4c with 1e). 
The more interesting compound among the miscellaneous structures 5 – 9 is the imidazole 
derivative 5. Compared to the agelasine analogs 1d – 1f, the whole pyrimidine ring is removed. This 
modification results in a less toxic compound with a broad antiprotozoal spectrum. It is worth noting 
that the benzimidazole derivative 6 is more toxic (MRC-5) and less active against L. infantum 
compared to the corresponding imidazole 5. 
 
Conclusions 
 
Agelasine D and several agelasine analogs and related structures were screened for inhibitory 
activity against P. falciparum, L. infantum, T. b. brucei and T. cruzi, as well as for cytotoxicity on 
MRC-5 fibroblast cells. Many compounds displayed high general toxicity. Nevertheless, two 
compounds (1d and 5) were identified as hits for leishmaniasis and two (2a and 5) for Chagas disease. 
Identification of the hits as well as other SAR data from this initial screening will be valuable for 
design of more potent and selective potential drugs against these neglected tropical diseases. 
 
Experimental  
 
Compounds 
 
All compounds studied were synthesized as described before; 1a, 1d, and 3b [20], 1b-1c, 1e-1k, 2a-
2b, 3a, 3c-3g, 4-8 [23], 1l-1m, 9 [22], 1n-1o, 2c [19]. Stock solutions were prepared in 100% DMSO 
at 20 mg/mL. 
 
Test plate production 
 
The experiments were performed in 96-well plates (Greiner) at four-fold dilutions in a dose-titration 
range of 64 μg/mL to 0.25 μg/mL. Dilutions were carried out by a programmable precision robotic 
station (BIOMEK 2000, Beckman, USA). Each plate also contained medium-controls (blanks: 0% 
growth), infected untreated controls (negative control: 100% growth) and reference controls (positive 
control). Tests were run in duplicate in two independent experiments. 
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Biological screening tests 
 
The integrated panel of microbial screens for the present study and the standard screening 
methodologies were adopted as have been described before [29]. Compounds with high cytotoxicity 
and related aspecificity across the different protozoa models were not titrated down to the exact IC50.  
 
Antiplasmodial activity  
 
The chloroquine-suceptible P. falciparum GHA-strain was used. Parasites were cultured in human 
erythrocytes A+ at 37 °C under a low oxygen atmosphere (3% O2, 4% CO2, and 93% N2) in a modular 
incubation chamber [30]. The culture medium was RPMI-1640, supplemented with 10% human serum. 
Two hundred microliters of infected human red blood cells suspension (1% parasitemia, 2% 
hematocrit) were added to each well of the plates with test compounds and incubated for 72 h. After 
incubation, test plates were frozen at -20 °C. Parasite multiplication was measured by the Malstat 
method [31]. One hundred microliters of Malstat reagent were transferred in a new plate and mixed 
with 20 μL of the hemolysed parasite suspension for 15 minutes at room temperature. After addition of 
20 μL NBT/PES solution and 2 h incubation in the dark, the absorbance was spectrophotometrically 
read at 655 nm (Biorad 3550-UV microplate reader). Percentage growth inhibition was calculated 
compared to the negative blanks.  
 
Antitrypanosomal activity  
 
T. b. brucei: Trypomastigotes of T. b. brucei Squib-427 strain (suramin-sensitive) were cultured at 
37 °C and 5% CO2 in Hirumi-9 medium [32], supplemented with 10% fetal calf serum (FCS). Assays 
were performed by adding 1.5×104 trypomastigotes/well. After 72 h incubation, parasite growth was 
assessed fluorimetrically by adding resazurin [33] for 24 h at 37 °C. Fluorescence was measured using 
a GENios Tecan fluorimeter (excitation 530 nm, emission 590 nm). 
T. cruzi: Tulahuen CL2 strain (nifurtimox-sensitive) was maintained on MRC-5 cells in minimal 
essential medium (MEM) supplemented with 20 mM L-Glutamine, 16.5 mM sodium hydrogen 
carbonate and FCS (5%) at 37 °C and 5% CO2. To determine in vitro anti-trypanosomal activity, 
4×103 MRC-5 cells and 4×104 parasites were added to each well of test plate with compound. After 
incubation at 37 °C for 7 days, parasite growth was assessed by adding of β-galactosidase substrate, 
chlorophenol red β-D-galactopyranoside [34] for 4 h at 37 °C. The color reaction was read at 540 nm 
and absorbance values were expressed as a percentage of the blank controls. 
 
Antileishmanial activity  
 
Leishmania infantum amastigotes (MHOM/ET 67) were collected from an infected donor hamster 
and used to infect primary peritoneal mouse macrophages. To determine in vitro antileishmanial 
activity, 3×104 macrophages were seeded in each well of a 96-well plate. After 48 h outgrowth, 5×104 
amastigotes/well were added and incubated for 2 h at 37 °C. Pre-diluted compounds were subsequently 
added and the plates were further incubated for 120 h at 37 °C and 5% CO2. Parasite burdens were 
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determined microscopically after Giemsa staining and expressed as a percentage of the blank controls 
without compound. 
 
Cytotoxicity assay   
 
MRC-5 SV2 cells, human fetal lung fibroblast, were cultivated in MEM, supplemented with L-
glutamine (20 mM), 16.5 mM sodium hydrogen carbonate and 5% FCS at 37 °C and 5% CO2. For the 
assay, 104 MRC-5 cells/well were seeded onto the test plates containing the pre-diluted compounds 
and incubated at 37 °C and 5% CO2 for 72 h. Cell viability was determined after addition of resazurin.  
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